Clinical Trial Update: Effects of Somatostatin on ADPKD Heart [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating somatostatin for heart-related outcomes in autosomal dominant polycystic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Somatostatin (somatostatin)

Snippet

Sponsor: Federico II University | Conditions: Autosomal Dominant Polycystic Kidney Disease, Glomerular Filtration Rate > 40 ml/Min | Phase 2, Phase 3 | Status: COMPLETED